Altimmune(ALT) - 2025 Q4 - Annual Results

Exhibit 99.1 Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third quarter 2026 Cash, cash equivalents and short-term investments of $274 million as of December 31, 2025; Balance sheet further strengthened through $75 million registered direct offering in ...